Wells Fargo Maintains Market Perform on Eli Lilly

Wells Fargo is out with its report today on Eli Lilly

, maintaining Market Perform. In a note to clients, Wells Fargo writes, "Investor day highlights pipeline candidates in diabetes, oncology, neurology, and autoimmune. Management reiterated 2011-14 minimum annual guidance of $20B in revenue, $3B net income, and $4B of operating cash flow and expects to return to growth in 2015. Recent launches, Japanese expansion, emerging markets, and Animal Health are expected to help offset lost revenue from patent expiries. Maintain Market Perform." At the time of posting, shares of LLY were trading at $37.42, down 0.29% from Thursday's close.